---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-013568"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2024-02-12T23:59:59+00:00"
generated_at: "2026-06-06T04:13:45.710018+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma Q3 FY2024 net loss narrows to $2.4M; cash runway extends to early 2026

## Summary
- Net loss of $2.4M ($0.21/share) vs $3.9M ($0.52) in prior-year quarter.
- R&D expenses decreased 44% YoY to $1.4M due to resource prioritization on GTX-104.
- Cash, equivalents and ST investments $25.1M; runway extended into 2nd calendar Q 2026.
- Pivotal STRIVE-ON Phase 3 trial enrollment ongoing; NDA submission on track for 1H 2025.
- Company secured $7.5M private placement in prior quarter to bolster balance sheet.

## SEC filing metadata
- accession: 0000950170-24-013568
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2024-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017024013568/0000950170-24-013568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017024013568/acst-20240212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-013568
- JSON: https://secwatch.observer/filing/0000950170-24-013568.json
- Plain text: https://secwatch.observer/filing/0000950170-24-013568.txt

## Key facts
- Earnings Releases
  Grace Therapeutics, Inc. reported the quarter ended December 31, 2023 results: net income $2.4 million, EPS $0.21 per share.
  - Period: the quarter ended December 31, 2023
  - Net income: $2.4 million
  - EPS: $0.21 per share
  - Result: reported results
  source text: The Company reported a net loss of $2.4 million, or $0.21 per share, for the three months ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017024013568/0000950170-24-013568-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.